X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Using this platform Eidos will be able to capitalize on BridgeBio’s global clinical development and regulatory expertise, its developing commercial infrastructure, and its broader capital base to reach more patients more effectively.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BridgeBio Pharma
Deal Size: $2,830.0 million Upfront Cash: $175.0 million
Deal Type: Merger October 05, 2020
Details:
Eidos is developing acoramidis (formerly AG10) as a potentially best-in-class treatment option for ATTR patients.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
